SCHEMBL27039747

SCHEMBL27039747

CSC=CC(=O)c1ccccn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.58
NPC1 O15118 4/20 0.58
RAB9A P51151 4/20 0.58
KDM4E B2RXH2 3/20 0.58
PKM P14618 3/20 0.58
LMNA P02545 3/20 0.58
KMT2A Q03164 3/20 0.52
ALDH1A1 P00352 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
MEN1 O00255 2/20 0.52
GPR52 Q9Y2T5 1/20 0.51
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
KRAS P01116 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MITF O75030 1/20 0.49
TP53 P04637 1/20 0.49
NAPRT Q6XQN6 1/20 0.48
P4HTM Q9NXG6 1/20 0.48
MAPK1 P28482 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30208792 0.80 MAPT (0.64) MAPTNPC1RAB9AKDM4EPKM
SCHEMBL10950289 0.80 MAPT (0.64) MAPTNPC1RAB9AKDM4EPKM
SCHEMBL10950293 0.80 MAPT (0.64) MAPTNPC1RAB9AKDM4EPKM
SCHEMBL22462223 0.78 MAPT (0.66) MAPTNPC1RAB9AKDM4EPKM
SCHEMBL30668590 0.78 MAPT (0.66) MAPTNPC1RAB9AKDM4EPKM
SCHEMBL11051347 0.77 KMT2A (0.55) MAPTNPC1RAB9AKDM4EPKM
SCHEMBL22478745 0.77 MAPT (0.61) MAPTNPC1RAB9AKDM4EPKM
SCHEMBL14305290 0.77 MAPT (0.61) MAPTNPC1RAB9AKDM4EPKM
SCHEMBL29601190 0.77 KMT2A (0.55) MAPTNPC1RAB9AKDM4EPKM
SCHEMBL19787945 0.77 MAPT (0.64) MAPTNPC1RAB9AKDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025891-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CELGENE CORPORATION 2024-01-25 US disclosed
CN-116547282-A Heterocyclic compounds and their use for the treatment of helminth infections and diseases 新基公司 2023-08-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025891-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CYP8B1, PAH, INHA MAPT 521/4885NPC1 2626/4885RAB9A 1887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.